Drug Pricing

Blog

Biden’s Non-Plan for Fighting Inflation

In a recent survey, Americans ranked inflation as the most urgent issue facing the country.  So, our ears perked up when Pres. Biden began laying out his plan to bring down inflation in his State of the Union address.  After listening to his speech, you can’t help but think that …

Commentary

Light starts to shine on opaque drug pricing tactics

Late last month, the Federal Trade Commission announced it would seek public comments on the ways pharmacy benefit managers distort the prices of prescription drugs. PBMs deserve the scrutiny, as they’re to blame for much of the rise in prescription drug costs. Insurers hire PBMs to negotiate drug prices with …

Commentary

High Healthcare Spending Doesn’t Bolster Case for Single-Payer

Does the United States spend too much on healthcare? A look at the lower levels of healthcare spending in peer countries like Canada and the United Kingdom would seem to indicate as much. But a closer look at those numbers reveals a far more complex story. Take the matter of …

Drug Pricing

Wayne Winegarden Discusses Prescription Drug Prices on Scripps National News

Watch PRI’s Wayne Winegarden, director of our Center for Medical Economics and Innovation, discuss efforts by the Federal Trade Commission to considering ordering large pharmacy benefits managers to study the competitive impact of contractual provisions, reimbursement adjustments, and other practices affecting drug prices on Scripps National News.

Commentary

The FDA Needs Reform – Biden’s Nominee Is Not the Person to Do It

When President Joe Biden nominated former Obama-era Food and Drug Administration Commissioner Dr. Robert Califf to return to his old post, he made what was widely seen as a safe, if uninspired, choice. He easily sailed through a Dec. 14 Senate committee hearing to vet him. “[Califf] gushed about his love of high-quality …

Drug Prices

NEW STUDY: Creating Two-Part Drug Pricing System Would Ensure Prices More Accurately Reflect How Patients

Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced by centralized organizations, argues a new report released today by the Center for Medical Economics …

Commentary

Build Back Better’s Drug Reforms Make American Health Care Worse

Last week, President Joe Biden emphasized the importance of the drug pricing proposals in the Democrats’ roughly $2 trillion Build Back Better spending package. “I think it’s safe to say that all of us, all of us, whatever our age, wherever we live, we can agree that prescription drugs are outrageously expensive …

Commentary

Comprehensive Regulatory Reform From The Bottom Up: The Case Of 340B

Using the ruse of “price negotiation”, the proponents of the Build Back Better legislation are pushing an ill-fated drug price control plan. Patients will bear exceptionally large costs should their idea of government-directed prices become law. These costs will include lower health outcomes due to reduced access to innovative drugs. …

Blog

Inflation, Drug Price Controls, and President Biden’s Build Back Better Program

Inflation is worrying Americans, and for good reason. The latest inflation report, the Consumer Price Index (CPI) released on November 10th, showed that prices were 6.2 percent higher in October 2021 compared to October 2020. More troubling, this was the fifth month in a row where the annual growth in …

Commentary

Democrats Abandon US Patients to Rescue Drug-Pricing Reform

Just a few days ago, it appeared that Democrats had given up on including prescription drug pricing reforms in their massive spending bill. But not anymore. In an eleventh-hour turn of events, congressional Democrats this week resurrected their long-standing desire to levy government price controls on prescription drugs. If lawmakers successfully deploy their latest …

Blog

Biden’s Non-Plan for Fighting Inflation

In a recent survey, Americans ranked inflation as the most urgent issue facing the country.  So, our ears perked up when Pres. Biden began laying out his plan to bring down inflation in his State of the Union address.  After listening to his speech, you can’t help but think that …

Commentary

Light starts to shine on opaque drug pricing tactics

Late last month, the Federal Trade Commission announced it would seek public comments on the ways pharmacy benefit managers distort the prices of prescription drugs. PBMs deserve the scrutiny, as they’re to blame for much of the rise in prescription drug costs. Insurers hire PBMs to negotiate drug prices with …

Commentary

High Healthcare Spending Doesn’t Bolster Case for Single-Payer

Does the United States spend too much on healthcare? A look at the lower levels of healthcare spending in peer countries like Canada and the United Kingdom would seem to indicate as much. But a closer look at those numbers reveals a far more complex story. Take the matter of …

Drug Pricing

Wayne Winegarden Discusses Prescription Drug Prices on Scripps National News

Watch PRI’s Wayne Winegarden, director of our Center for Medical Economics and Innovation, discuss efforts by the Federal Trade Commission to considering ordering large pharmacy benefits managers to study the competitive impact of contractual provisions, reimbursement adjustments, and other practices affecting drug prices on Scripps National News.

Commentary

The FDA Needs Reform – Biden’s Nominee Is Not the Person to Do It

When President Joe Biden nominated former Obama-era Food and Drug Administration Commissioner Dr. Robert Califf to return to his old post, he made what was widely seen as a safe, if uninspired, choice. He easily sailed through a Dec. 14 Senate committee hearing to vet him. “[Califf] gushed about his love of high-quality …

Drug Prices

NEW STUDY: Creating Two-Part Drug Pricing System Would Ensure Prices More Accurately Reflect How Patients

Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced by centralized organizations, argues a new report released today by the Center for Medical Economics …

Commentary

Build Back Better’s Drug Reforms Make American Health Care Worse

Last week, President Joe Biden emphasized the importance of the drug pricing proposals in the Democrats’ roughly $2 trillion Build Back Better spending package. “I think it’s safe to say that all of us, all of us, whatever our age, wherever we live, we can agree that prescription drugs are outrageously expensive …

Commentary

Comprehensive Regulatory Reform From The Bottom Up: The Case Of 340B

Using the ruse of “price negotiation”, the proponents of the Build Back Better legislation are pushing an ill-fated drug price control plan. Patients will bear exceptionally large costs should their idea of government-directed prices become law. These costs will include lower health outcomes due to reduced access to innovative drugs. …

Blog

Inflation, Drug Price Controls, and President Biden’s Build Back Better Program

Inflation is worrying Americans, and for good reason. The latest inflation report, the Consumer Price Index (CPI) released on November 10th, showed that prices were 6.2 percent higher in October 2021 compared to October 2020. More troubling, this was the fifth month in a row where the annual growth in …

Commentary

Democrats Abandon US Patients to Rescue Drug-Pricing Reform

Just a few days ago, it appeared that Democrats had given up on including prescription drug pricing reforms in their massive spending bill. But not anymore. In an eleventh-hour turn of events, congressional Democrats this week resurrected their long-standing desire to levy government price controls on prescription drugs. If lawmakers successfully deploy their latest …

Scroll to Top